#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary neuropathic amyloidosis Polyneuropathy Germ cell cancer Meningococcal immunisation Small cell lung cancer extensive stage Mantle cell lymphoma Mastocytosis Interstitial lung disease Glioblastoma Cholangitis sclerosing Propionic acidaemia Chondrosarcoma Dementia Guillain-Barre syndrome Follicle centre lymphoma follicular grade I, II – III More trials…

    Learn about Rare Diseases

    Angiosarcoma non-metastatic – Trials in Disease Focal segmental glomerulosclerosis – Treatment Alport’s syndrome Mantle cell lymphoma refractory – Trials in Disease Cerebral arteriovenous malformation haemorrhagic – Diagnostics Familial haemophagocytic lymphohistiocytosis – Treatment Adrenocortical carcinoma Richter’s syndrome – Basic Information Carcinoid syndrome – Treatment Familial amyotrophic lateral sclerosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    CEFTAROLINE FOSAMIL Terbinafine Ttf-Ngr Mometasone Furoate Ph. Eur. Flucloxacillin Somatropin Disodium Levofolinate Alnuctamab Simeticone Vancomycin Voxelotor ABY-271 Betamethasone Dipropionate Deucrictibant Telisotuzumab Vedotin [18F]-Altanserin Ritonavir Apalutamide Tezacaftor INF904 More therapies…

    Learn about Your Condition

    Giardiasis Cold type haemolytic anaemia Marfan's syndrome Appendicitis Thrombocytopenia Connective tissue disorder Anogenital dysplasia Carcinoid syndrome Chronic kidney disease Cerebral palsy Congenital myopathy Fibrosarcoma metastatic Hepatitis D Hypertension Wolfram syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Pembrolizumab, Lenvatinib, and Chemotherapy for Patients with Metastatic Esophageal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • ANHYDROUS CALCIUM FOLINATE
    • Cisplatin
    • Fluorouracil
    Denmark France Hungary Italy Romania Spain

  • Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Xevinapant
    Belgium France Germany Ireland Italy The Netherlands +3

  • Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Luspatercept
    • Epoetin Alfa
    Austria Belgium Czechia France Germany Greece +8

  • Study on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    • Quavonlimab
    Italy Poland Spain

  • Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ticagrelor
    • Milvexian
    • Prasugrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study on Volixibat for Treating Itching in Patients with Primary Biliary Cholangitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Primary biliary cholangitis
    Investigated Drugs:
    • Volixibat
    Belgium France Germany Italy The Netherlands Spain

  • Study of Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Durvalumab
    • Infliximab
    • Mycophenolate Mofetil
    France Germany Italy Spain

  • Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Milvexian
    • Andexanet Alfa
    • Apixaban
    Belgium Bulgaria Croatia Czechia Denmark Estonia +13

  • Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

    Not recruiting

    3 1
    Investigated Drugs:
    • Rifaximin
    Belgium Bulgaria France Germany Hungary Italy +2

  • Study of Oral NX-13 for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • 1,3,5-Tris(6-Methylpyridin-2-Yloxy)Benzene
    Belgium Italy Poland
Previous Page
1 … 63 64 65 66 67 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!